- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Eliquis fast tracked by NICE

The use of Eliquis (apixaban) on the NHS has been recommended by NICE as a treatment option for the prevention of venous thromboembolism (VTE) for those who have had a total hip or knee replacement.

The treatment was licensed just six months ago but NICE fast tracked the final draft guidance after the convenient drug was proven to help prevent blood clots.

Professor Carole Longson, NICE Health Technology Evaluation Centre Director, says t hat Eliquis “is a clinically and cost effective option”.

Patients undergoing hip and knee replacement surgery have a high risk of developing VTE – a term to describe the conditions of deep vein thrombosis and pulmonary embolism.

Last year more than 120,000 hip and knee replacements were carried out in England and Wales. These procedures carry a high risk of VTE and require effective anticoagulation to protect patients from potentially fatal clots developing.

“We are pleased to have been able to produce final draft guidance on the use of apixaban just six months after it received its license for the prevention of VTE in patients who have undergone planned hip and knee surgery,” said Professor Longson.

Eliquis is manufactured by Pfizer and Bristol-Myers Squibb.

- Advertisement -


- Advertisement -



Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription